Binosto is a drug owned by Radius Health Inc. It is protected by 3 US drug patents filed from 2013 to 2021. Out of these, 1 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 05, 2031. Details of Binosto's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9592195 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Dec, 2031
(6 years from now) | Active |
| US7488496 | Effervescent compositions comprising bisphosphonates and methods related thereto |
Aug, 2023
(1 year, 9 months ago) |
Expired
|
| US7964212 | Effervescent compositions comprising phosphonates and methods related thereto |
Mar, 2023
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Binosto's patents.
Latest Legal Activities on Binosto's Patents
Given below is the list of recent legal activities going on the following patents of Binosto.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Apr, 2024 | US9592195 |
| Expire Patent Critical | 24 Jul, 2023 | US7964212 |
| Maintenance Fee Reminder Mailed Critical | 06 Feb, 2023 | US7964212 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 05 May, 2020 | US7488496 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 May, 2020 | US9592195 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Oct, 2018 | US7964212 |
| Recordation of Patent Grant Mailed Critical | 14 Mar, 2017 | US9592195 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Mar, 2017 | US9592195 |
| Email Notification Critical | 23 Feb, 2017 | US9592195 |
| Issue Notification Mailed Critical | 22 Feb, 2017 | US9592195 |
US patents provide insights into the exclusivity only within the United States, but Binosto is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Binosto's family patents as well as insights into ongoing legal events on those patents.
Binosto's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Binosto's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 05, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Binosto Generic API suppliers:
Alendronate Sodium is the generic name for the brand Binosto. 16 different companies have already filed for the generic of Binosto, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Binosto's generic
Alternative Brands for Binosto
Binosto which is used for treating symptoms of depression and anxiety., has several other brand drugs using the same active ingredient (Alendronate Sodium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Merck |
| |
| Organon |
| |
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Alendronate Sodium, Binosto's active ingredient. Check the complete list of approved generic manufacturers for Binosto
About Binosto
Binosto is a drug owned by Radius Health Inc. It is used for treating symptoms of depression and anxiety. Binosto uses Alendronate Sodium as an active ingredient. Binosto was launched by Radius in 2012.
Approval Date:
Binosto was approved by FDA for market use on 12 March, 2012.
Active Ingredient:
Binosto uses Alendronate Sodium as the active ingredient. Check out other Drugs and Companies using Alendronate Sodium ingredient
Treatment:
Binosto is used for treating symptoms of depression and anxiety.
Dosage:
Binosto is available in tablet, effervescent form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 70MG BASE | TABLET, EFFERVESCENT | Prescription | ORAL |